BioCorRx Launches R&D Initiative to Pursue FDA Approval for Naltrexone Implant
BioCorRx Inc. (OTC:BICX), developer of the BioCorRx® Recovery Program, a non-addictive medication-assisted treatment (MAT) program used in the treatment of alcohol and opioid addiction, announced today it is establishing a Research and Development initiative in order to seek U.S. Food and Drug Administration (FDA) approval for its naltrexone implant.
View full press release